DEFA14A: AtriCure Defends Executive Pay Practices Amidst ISS and Glass Lewis Opposition

AtriCure urges stockholders to approve its Say-on-Pay proposal, addressing concerns raised by ISS and Glass Lewis regarding executive compensation, particularly the CEO's special performance share unit award.

Summary

• AtriCure is seeking stockholder approval for its Say-on-Pay proposal despite recommendations against it from Institutional Shareholder Services (ISS) and Glass Lewis.
• The company defends its executive compensation philosophy, emphasizing a pay-for-performance approach designed to align executive interests with those of long-term stockholders.
• A key point of contention is a special performance share unit (PSU) award granted to CEO Michael Carrel in 2024, which ISS and Glass Lewis question the rationale and size of.
• AtriCure argues the award incentivizes long-term growth and is tied to rigorous stock price appreciation targets, with hurdles ranging from $50 to $100 per share over a four-year period.
• The company also addresses concerns about disclosure of performance metrics, clarifying that revenue CAGR targets were disclosed in the Form 10-K and that detailed objectives for the annual incentive plan were provided in the proxy statement.
• AtriCure highlights its 2024 performance, including revenue of $465.3 million (a 16.5% increase) and adjusted EBITDA of $31.1 million (a 60% improvement).
• The company emphasizes that a significant portion of executive pay is at risk and tied to multiple performance metrics, including revenue growth and total shareholder return.

Sentiment

Score: 6

Explanation: The document presents a defensive stance, attempting to justify executive compensation practices in the face of external criticism. While the company highlights positive financial results, the need to address concerns from ISS and Glass Lewis suggests underlying issues.

Positives

• AtriCure's executive compensation program is designed to align executive interests with those of long-term stockholders through performance-based incentives.
• The CEO's special PSU award includes rigorous, predetermined performance conditions tied to stock price appreciation.
• The company has provided additional disclosure regarding performance metrics and objectives in response to concerns raised by ISS and Glass Lewis.
• AtriCure achieved significant revenue growth and improved profitability in 2024.
• The company maintains double-trigger change in control agreements, aligning executive pay with stockholder feedback.

Negatives

• ISS and Glass Lewis have recommended against AtriCure's Say-on-Pay proposal, raising concerns about the CEO's special PSU award and disclosure practices.
• The company acknowledges that its current market valuation may not fully reflect its financial performance and market opportunity.

Risks

• Failure to obtain stockholder approval for the Say-on-Pay proposal could lead to negative publicity and potential challenges to the company's executive compensation program.
• Continued scrutiny from ISS and Glass Lewis could impact investor confidence and the company's ability to attract and retain top executive talent.
• The company's ability to achieve the ambitious stock price targets associated with the CEO's PSU award is subject to market conditions and execution risks.

Future Outlook

The company aims to continue driving revenue growth and improving profitability through market penetration, product adoption, and new product launches.

Management Comments

• We are writing to ask for your support by voting in accordance with the recommendations of our Board of Directors (the Board) on all of the Company's proxy proposals in the Proxy Statement.
• We believe that each proxy advisory firms standardized voting policies and say-on-pay analyses assess our program through the lens of a much more mature company than we currently are and on the basis of peer companies that do not truly reflect AtriCure's market peers.
• The Compensation Committee believes that our peer group represents companies in our broad labor market for talent, while maintaining comparability with sufficient group size to avoid distortions from a single company and ensuring sufficient and credible data.

Industry Context

The Say-on-Pay proposal and the scrutiny from ISS and Glass Lewis are common occurrences for publicly traded companies, particularly those with complex executive compensation structures. Companies often need to justify their pay practices to shareholders and proxy advisory firms.

Comparison to Industry Standards

• It is difficult to compare AtriCure's executive compensation directly to industry standards without knowing the specific peer group used by the Compensation Committee.
• The document mentions that the proxy advisory firms use peer groups that do not accurately reflect AtriCure's market peers, suggesting that comparisons based on those peer groups may be misleading.
• The document references similarly structured grants at other companies, but does not provide specific examples for comparison.

Stakeholder Impact

• The outcome of the Say-on-Pay vote could impact shareholder confidence and the company's reputation.
• Executive compensation practices can influence employee morale and the company's ability to attract and retain talent.
• The company's financial performance and strategic decisions ultimately impact customers, suppliers, and other stakeholders.

Next Steps

• Stockholders will vote on the Say-on-Pay proposal at the Annual Meeting on May 19, 2025.
• The company will continue to engage with investors and proxy advisory firms to address concerns about its executive compensation program.

Key Dates

Keywords

Say-on-Pay, Executive Compensation, Performance Share Units, ISS, Glass Lewis, Revenue Growth, EBITDA, Stockholder Value, Proxy Statement, AtriCure